NcXHF

NEW TARGETED THERAPIES FOR iNHL
a PI3K-, inhibitor, in patients with relapsed/refractory iNHL. Presented
at: The 56th Annual Meeting of the American Society of Hematology;
December 2014; San Francisco, California.
38. O’Brien S, Patel M, Kahl BS, et al. Duvelisib (IPI-145), a PI3K-, inhibitor,
is clinically active in patients with relapsed/refractory chronic
lymphocytic leukemia. Presented at: The 56th Annual Meeting of the
American Society of Hematology; December 2014; San Francisco,
California.
39. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction
pathway as a target for cancer therapy. Oncogene. 2000;19:6680-6686.
40. Conconi A, Raderer M, Franceschetti S, et al. Clinical activity of everolimus
in relapsed/refractory marginal zone B-cell lymphomas: results of a
phase II study of the International Extranodal Lymphoma Study Group.
Br J Haematol. 2014;166:69-76.
41. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II
trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or
refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89:
237-242.
42. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in
non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of
Chicago phase II consortium. J Clin Oncol. 2010;28:4740-4746.
43. Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/
refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL) with everolimus results in clinical responses and mobilization of
CLL cells into the circulation. Cancer. 2010;116:2201-2207.
44. Sharma A, Janocha AJ, Hill BT, et al. Targeting mTORC1-mediated
metabolic addiction overcomes fludarabine resistance in malignant B
cells. Mol Cancer Res. 2014;12:1205-1215.
45. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in
relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32-42.
46. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for
elderly patients with chronic lymphocytic leukaemia or small lymphocytic
lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet
Oncol. 2014;15:48-58.
47. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in
previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:
213-223.
48. Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a
Phase III study of ibrutinib in combination with bendamustine and
rituximab in relapsed/refractory chronic lymphocytic leukemia. Future
Oncol. 2015;11:51-59.
49. Treon SP, et al. A prospective multicenter study of the Bruton’s tyrosine
kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s
macroglobulinemia. Paper presented at: 55th Annual ASH
Meeting and Exposition; December 2013; New Orleans, LA.
50. Bartlett NL, LaPlant BR, Qi J, et al. Ibrutinib monotherapy in relapsed/
refractory follicular lymphoma (FL): preliminary results of a Phase 2
Consortium (P2C) trial. Paper presented at: 56th Annual ASH Meeting
and Exposition; December 2014; San Francisco, CA.
51. Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors
in clinical development. J Hematol Oncol. 2013;6:59.
52. Akinleye A, Furqan M, Adekunle O. Ibrutinib and indolent B-cell lymphomas.
Clin Lymphoma Myeloma Leuk. 2014;14:253-260.
53. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory
drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24:
22-32.
54. Nowakowski GS, Ansell SM. Therapeutic targeting of microenvironment
in follicular lymphoma. Hematology Am Soc Hematol Educ Program.
2014;2014;169-173.
55. Chang XB, Stewart AK. What is the functional role of the thalidomide
binding protein cereblon? Int J Biochem Mol Biol. 2011;2:287-294.
56. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of
immune-modulatory drugs thalidomide, lenalidomide and pomalidomide
in multiple myeloma. Leuk Lymphoma. 2013;54:683-687.
57. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes
the cereblon-dependent destruction of Ikaros proteins. Science.
2014;343:305-309.
58. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy
produces durable responses in relapsed or refractory indolent
non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27:5404-5409.
59. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide
and rituximab in untreated indolent lymphoma: an open-label, phase 2
trial. Lancet Oncol. 2014;15:1311-1318.
60. Gertz MA. Waldenström macroglobulinemia: 2013 update on diagnosis,
risk stratifıcation, and management. Am J Hematol. 2013;88:703-
711.
61. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab
in Waldenstrom’s macroglobulinemia. Clin Cancer Res. 2009;15:
355-360.
62. Deshaies RJ. Proteotoxic crisis, the ubiquitin-proteasome system, and
cancer therapy. BMC Biol. 2014;12:94.
63. O’Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience
with the novel proteasome inhibitor bortezomib in patients with indolent
non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol.
2005;23:676-684.
64. Di Bella N, Taetle R, Kolibaba K, et al. Results of a phase 2 study of
bortezomib in patients with relapsed or refractory indolent lymphoma.
Blood. 2010;115:475-480.
65. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study
of weekly or twice-weekly bortezomib plus rituximab in patients with
relapsed or refractory follicular or marginal-zone B-cell lymphoma.
J Clin Oncol. 2009;27:5023-5030.
66. Coiffıer B, Osmanov EA, Hong X, et al. Bortezomib plus rituximab
verus rituximab alone in patients with relapsed, rituximab-naïve or
rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Lancet Oncol. 2011;12:773-784.
67. Evens AM, Smith MR, Lossos IS, et al. Frontline bortezomib and rituximab
for the treatment of newly diagnosed high tumour burden indolent
non-Hodgkin lymphoma: a multicentre phase II study. Br J
Haematol. 2014;166:514-520. Epub 2014 Apr 25.
68. Treon SP, Tripsas CK, Meid K, et al. Carfılzomib, rituximab, and dexamethasone
(CaRD) treatment offers a neuropathy-sparing approach for
treating Waldenström’s macroglobulinemia. Blood. 2014;124:503-510.
69. Alsina M, Trudel S, Furman RR, et al. A phase I single-agent study of
twice-weekly consecutive-day dosing of the proteasome inhibitor carfılzomib
in patients with relapsed or refractory multiple myeloma or lymphoma.
Clin Cancer Res. 2012;18:4830-4840.
70. Oki Y, Buglio D, Fanale M, et al. Phase I study of panobinostat plus
everolimus in patients with relapsed or refractory lymphoma. Clin Cancer
Res. 2013;19:6882-6890.
71. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat
for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma
and mantle cell lymphoma. J Clin Oncol. 2011;29:1198-1203.
72. Malik A, Shoukier M, Garcia-Manero G, et al. Azacitidine in
fludarabine-refractory chronic lymphocytic leukemia: a phase II study.
Clin Lymphoma Myeloma Leuk. 2013;13:292-295.
73. Blum KA, Liu Z, Lucas DM, et al. Phase I trial of low dose decitabine targeting
DNA hypermethylation in patients with chronic lymphocytic leukaemia and
non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence
of DNA hypomethylation. Br J Haematol. 2010;150:189-195.
74. Coiffıer B, Morschhauser F, Dupuis J, et al. Phase I study cohort evaluating
an optimized administration schedule of SAR3419, an anti-CD19
DM4-loaded antibody drug conjugate (ADC), in patients (pts) with
CD19 positive relapsed/refractory b-cell non-Hodgkin’s lymphoma
asco.org/edbook | 2015 ASCO EDUCATIONAL BOOK
e373